United Therapeutics (UTHR) EPS (Basic) (2009 - 2026)

United Therapeutics has disclosed EPS (Basic) across 18 years of filings, most recently posting $6.32 for Q1 2026.

• EPS (Basic) for Q1 2026 came in at $6.32, down 11.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.28 (up 8.12% YoY), and the FY2025 annual result was $30.13, up 13.96% from the prior year.
• EPS (Basic) came in at $6.32 for Q1 2026 at United Therapeutics, down from $8.37 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $8.37 in Q4 2025 to a low of $2.56 in Q2 2022.
• The 5-year median for EPS (Basic) is $6.26 (2024), against an average of $5.88.
• Peak annual rise in EPS (Basic) reached 742.86% in 2022, while the deepest fall reached 33.51% in 2022.
• United Therapeutics' EPS (Basic) stood at $2.84 in 2022, then soared by 61.97% to $4.6 in 2023, then soared by 45.87% to $6.71 in 2024, then advanced by 24.74% to $8.37 in 2025, then decreased by 24.49% to $6.32 in 2026.
• The last three EPS (Basic) figures came in at $6.32 (Q1 2026), $8.37 (Q4 2025), and $7.73 (Q3 2025), per Business Quant data.